STOCK TITAN
  1. Home
  2. Sec-filings
  3. OTLK
  4. [Form 4] Outlook Therapeutics, Inc. Insider Trading Activity

Director at Outlook Therapeutics (OTLK) makes open-market share purchase

Filing Impact
(Neutral)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

Outlook Therapeutics, Inc. director Sukhtian Faisal Ghiath reported an open-market purchase of 122,174 shares of Common Stock at an average price of $0.4093 per share. Following this transaction, he directly owns a total of 125,574 Common Stock shares.

Positive

  • None.

Negative

  • None.
Insider Sukhtian Faisal Ghiath
Role null
Bought 122,174 shs ($50K)
Type Security Shares Price Value
Purchase Common Stock 122,174 $0.4093 $50K
Holdings After Transaction: Common Stock — 125,574 shares (Direct, null)
Footnotes (1)
Shares purchased 122,174 shares Open-market purchase of Common Stock
Purchase price $0.4093 per share Average price for the reported buy
Shares owned after 125,574 shares Director’s direct Common Stock holdings post-transaction
Net buy shares 122,174 shares Net buy activity in the reporting period
open-market purchase financial
"reported an open-market purchase of 122,174 shares of Common Stock"
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Common Stock financial
"122,174 shares of Common Stock at an average price of $0.4093"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Form 4 regulatory
"What insider transaction did Outlook Therapeutics (OTLK) report on this Form 4?"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Sukhtian Faisal Ghiath
(Last)(First)(Middle)
C/O OUTLOOK THERAPEUTICS, INC.
111 S. WOOD AVE, UNIT #100
(Street)
ISELIN NEW JERSEY 08830
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Outlook Therapeutics, Inc. [ OTLK ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/27/2026P122,174A$0.4093125,574D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Lawrence Kenyon, Attorney-in-Fact05/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Outlook Therapeutics (OTLK) report on this Form 4?

Outlook Therapeutics director Sukhtian Faisal Ghiath reported buying 122,174 shares of Common Stock in an open-market purchase at $0.4093 per share, increasing his directly held position to 125,574 shares after the transaction.

Who is the insider involved in the latest Outlook Therapeutics (OTLK) Form 4 filing?

The insider is Sukhtian Faisal Ghiath, a director of Outlook Therapeutics, Inc. He reported a single open-market purchase of 122,174 Common Stock shares at $0.4093 per share, bringing his direct holdings to 125,574 shares following the trade.

How many Outlook Therapeutics (OTLK) shares did the director buy and at what price?

Director Sukhtian Faisal Ghiath bought 122,174 shares of Outlook Therapeutics Common Stock at an average price of $0.4093 per share. This open-market purchase increased his total directly owned shares to 125,574 after the reported transaction.

What are the director’s Outlook Therapeutics (OTLK) holdings after the reported Form 4 transaction?

After the reported open-market purchase, director Sukhtian Faisal Ghiath directly owns 125,574 shares of Outlook Therapeutics Common Stock. This total reflects the addition of 122,174 shares acquired at $0.4093 per share in the disclosed transaction.

Was the Outlook Therapeutics (OTLK) Form 4 transaction a buy or a sell?

The Form 4 shows a buy transaction. Director Sukhtian Faisal Ghiath executed an open-market purchase of 122,174 Common Stock shares at $0.4093 per share, resulting in net buy activity and total direct holdings of 125,574 shares afterward.